1. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–2.
5. Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 2017;153:812–26.
11. Várady G, Cserepes J, Németh A, Szabó E, Sarkadi B. Cell surface membrane proteins as personalized biomarkers: where we stand and where we are headed. Biomark Med. 2013;7:803–19.
16. Zhang X, Cheng Q, Yin H, Yang G. Regulation of autophagy and EMT by the interplay between p53 and RAS during cancer progression. Int J Oncol. 2017;51:18–24.
25. Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9:765–79.
31. Kim HR, Seo CW, Han SJ, Kim J. C4orf47 is a novel prognostic biomarker and correlates with infiltrating immune cells in hepatocellular carcinoma. Biomed Sci Lett. 2023;29:11–25.
32. Kim HR, Seo CW, Lee JH, Han SJ, Kim J. SAMD13 as a novel prognostic biomarker and its correlation with infiltrating immune cells in hepatocellular carcinoma. Biomed Sci Lett. 2022;28:260–75.
34. Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv Cancer Res. 2011;110:107–39.